All News
Is there any data about the safety of 8000u of vitamin A daily? Just asking because I have no idea #ACR19 @RheumNow https://t.co/aLtCOgujdK
Philip Robinson philipcrobinson ( View Tweet)
Gout increases risk of fatal & non-fatal CVD events (in pop without previous CVD events)
No obvious protection from using Allopurinol
Population level study
#ACR19 @rheumnow Abst2732 https://t.co/yQu0PjkmIN
Dr Irwin Lim _connectedcare ( View Tweet)
Spending and price trending of bDMARDs. https://t.co/gB6xjvialr #ACR19 @RheumNow plenary#2731 https://t.co/YNpwYvTu1y
Dr. Rachel Tate uptoTate ( View Tweet)
Abstr# 2156: Something I had never heard of — Yao Syndrome.
This is an adult onset (mean 25.9yo at presentation) autoinflammatory syndrome associated with NOD2 mutations. #ACR19 @RheumNow https://t.co/J71t6uqrSx
Dr. Paul Sufka psufka ( View Tweet)
"We are all using biosimilars," said Dr. Bykerk, since TNFi approved in the 1990s have faced antigenic drift and changed over the years...
#ACR19 @RheumNow
Jonathan Hausmann MD hausmannMD ( View Tweet)
Abstract L06 shows the efficacy of Emapalumab, an IFN-γ mAb, when given to 9 systemic JIA pts who developed macrophage activation syndrome. Highly effective showing ability to lower steroid use #ACR19
#ACRBest https://t.co/OXTwpkyhlq
Dr. John Cush RheumNow ( View Tweet)
Yes, you read that right US$5,000,000,000 increase in biological DMARD spending #ACR19 @RheumNow Abs 2731 https://t.co/9Ew5II282Y
Philip Robinson philipcrobinson ( View Tweet)
#ACR19 Abst#2729 Plenary: Ixekizumab in NR-axSpA
Improved ASAS40 at wk16 (32% vs 12% PLBO, NNT~4). Wk52 open label f/u available, but hard to interpret
Remember this is a different population (non radiographic) than the upadacitinib trial that was also presented
@RheumNow https://t.co/tkYEfiqj7h
Mike Putman EBRheum ( View Tweet)
Abstr# 2612: Minocycline as an option for refractory calcinosis in scleroderma. 43% of patients reported some improvement. With few options available, this would be something to consider. #ACR19 @rheumnow https://t.co/yXvmUwaxzU
Dr. Paul Sufka psufka ( View Tweet)
We know ovarian insuff with cyclophosphamide is dose-related, but in SLE data from @EmoryUniversity @emoryhealthcare the absolute numerical diff between success & failure is tighter than I imagined. Other factors at play?
Also: time heals some wounds...
#ACR19 ABST2293 @RheumNow https://t.co/wI3S4ljjOJ
David Liew drdavidliew ( View Tweet)
Dr. Suzanne Li discusses juvenile localized scleroderma disease activity at #ACR19: jLS can cause severe damage. There is no universal activity feature for jLS so need to assess multiple features, such as
-Erythema
-Violaceous color
-Waxy white/yellow
#pedsrheum @RheumNow https://t.co/BpszRgHhyr
Dr. Erin Tree DrTinyTree ( View Tweet)
Ixekizumab in nrAXSpa
Outcomes met. Another positive trial
#ACR19 @rheumnow Abst2729 https://t.co/VVUKSi6sCQ
Dr Irwin Lim _connectedcare ( View Tweet)
Ixekizumab in nrAXSpa: COAST-X
switch at wk16 for 52wk study
IXE 2wkly vs 4wkly vs PBO
303pts
#ACR19 @rheumnow Abst2729
Dr Irwin Lim _connectedcare ( View Tweet)
@KDAO2011 teaching us about SLE @RheumNow #ACR19 it’s almost your last chance to swing by the rheumnow booth! https://t.co/pBdFAwGXtm
Dr. Rachel Tate uptoTate ( View Tweet)
Dr Atul Deodhar wows the crowd at #ACR19 showing abtract #2729 Ixekizumab in Non-Radiographic Axial Spondyloarthritis: Phase 3 Trial showing IXE is effective by ASAS40. https://t.co/Bcb20FYNoH
Dr. John Cush RheumNow ( View Tweet)
How should VECTRA be used, if at all?
-Bathon I don't use VECTRA routinely, it's as good as your physical exam.
-Bykerk: I've yet to find a good reason to use it.
-Emery ::no comment::
-Mikuls: I don't think there's a place in my clinic to use it.
#ACR19 @RheumNow
Jonathan Hausmann MD hausmannMD ( View Tweet)
@cappelliMD @Richter_MD @LCalabreseDO @CCalabreseDO @lexmeara @UmaThanaMD Nice work @Richter_MD - such an important phenomenon. It’s always something nice to tell my melanoma irAE patients: your arthritis might be nasty, but at least there’s a substantive upside!
#ACR19 ABST2137 @RheumNow
(sorry to miss you in person!) https://t.co/x1T9n9eekG
David Liew drdavidliew ( View Tweet)
38yo F with seroneg RA on 3x therapy with synovitis. What tx do you choose?
-Bathon: Confirm dx, use biologic, avoid ritux
-Bykerk: Ask about JIA, use TNF, JAK, IL-6
-Emery: Not ritux. Use steroids, consider TNFi, urgent tx is not needed
-Mikuls: Agree with above
#ACR19 @RheumNow
Jonathan Hausmann MD hausmannMD ( View Tweet)
@RheumNow Should note this was not the first JAKi in this space; similar trial using tofacitinib in 2017 https://t.co/NrEul0wLp9
Mike Putman EBRheum ( View Tweet)
#ACR19 Abst#2728 Plenary: Upadacitinib RCT in AnkSpa
Improved ASAS40 at wk14 (52% v 26% PLBO, NNT~4) and SPARCC MRI Scores.
Good safety profile but too small a trial to assess properly
Overall an encouraging result, JAKi impacting yet another disease!
@RheumNow https://t.co/GtB9wHuoNp
Mike Putman EBRheum ( View Tweet)